Skład ciała osób w różnym wieku z uwzględnieniem 60+ rekreacyjnie uprawiających pływanie

Wstęp: Artykuł prezentuje wyniki analiz dotyczących składu masy ciała ludzi w różnym wieku z uwzględnieniem osób 60+ uprawiających regularny trening pływacki. Cel: Celem pracy była analiza porównawcza składu ciała pomiędzy badanymi podzielonymi na grupy w różnym wieku. W związku z tak określonym celem sformułowano następującą hipotezę badawczą: osoby uprawiające pływanie w grupie Masters różnią się pod względem komponentów składu ciała w zależności od grupy wiekowej. Materiał: Badaniami objęto n=86 osób dorosłych, w tym 32 kobiet i 54 mężczyzn. Badania zostały przeprowadzone z zastosowaniem metody impedancji w oparciu o narzędzie jakim jest analizator składu ciała InBody 270. Dokonano analizy ośmiu wskaźników dotyczących komponentów ciała osób uprawiających pływanie w grupie Masters. Wyniki: Uzyskane wyniki wykazały, iż u kobiet parametry składu ciała wraz z wiekiem nieznacznie się zmieniają. W porównywanych grupach prezentują się na zbliżonym poziomie. Odmiennie jest w grupie badanych mężczyzn, w której, wskaźniki PBF (Procent tkanki tłuszczowej), FFM (Masa beztłuszczowa) prawego ramienia FFM (Masa beztłuszczowa) lewego ramienia, BFM (Masa tkanki tłuszczowej) lewego ramienia, BFM% (Masa tkanki tłuszczowej) lewego ramienia, poziom tłuszczu wisceralnego, jak również wynik InBody wykazały różnice istotne statystycznie. Wnioski: Wśród osobników płci męskiej, wraz z wiekiem, narasta zróżnicowanie pod względem ogólnej zawartości tkanki tłuszczowej, jak również pogłębiają się różnice w jej anatomicznym rozmieszczeniu mierzone za pomocą wskaźników dystrybucji. U badanych mężczyzn, dysproporcja wartości analizowanych parametrów była znaczna i określała zawartość tkanki nieaktywnej, stawiając grupę mężczyzn po sześćdziesiątym roku życia jako tę o zwiększonej zawartości tkanki tłuszczowej.Introduction: The article presents the results of a study analyzing body composition in different age groups, including 60+ seniors who regularly participate in swimming training. Study aim: The aim of this study was to compare the body composition of adults divided into different age groups. The research hypothesis postulating that Masters swimmers are characterized by age-dependent differences in body composition was tested. Materials and Methods: A total of 86 adults, including 32 women and 54 men, participated in the study. Body composition was determined by bioelectrical impedance with the InBody 270 analyzer. Eight body composition parameters were evaluated in Masters swimmers. Results: The results revealed minor age-related changes in the body composition of female participants. The analyzed parameters were similar in the compared groups of females. In contrast, significant differences in percent body fat (PBF) values, right-arm fat free mass% (FFM%) values, left-arm FFM% values, left-arm body fat mass% (BFM%) values, left-arm BFM values and visceral fat level were observed among the surveyed males. Conclusions: In men, the differences in Percent Body Fat and the anatomic distribution of adipose tissue measured with the relevant indicators increased with age. In male participants, considerable disproportions were observed in the content of inactive adipose tissue, and the accumulation of adipose tissue was higher in men older than 60

Nivolumab for relapsed/refractory classical Hodgkin lymphoma after brentuximab vedotin failure – Polish Lymphoma Research Group real-life experience

AimPolish centers analyzed retrospectively the real-life experience with nivolumab in relapsed/refractory (R/R) classical Hodgkin lymphoma (cHL) patients, after brentuximab vedotin (BV ) failure. BackgroundDespite the effective frontline treatment, for cHL patients relapsing after autologous stem cell transplantation, the only effective strategy remains the novel agents. Nivolumab, a checkpoint inhibitor, demonstrates the clinical benefit with an acceptable safety profile. Materials and methodsRetrospective analysis included 16 adult patients with R/R cHL after BV failure. All patients received single-agent nivolumab 3 mg/kg every 2 weeks until disease progression or unacceptable toxicity. ResultsAfter six cycles of nivolumab the overall response rate was 81% (complete remission rate of 56%, partial remission rate of 25%). The median PFS was not reached after a median follow-up of 19 months. Adverse events (AEs) of any grade occurred in 12 patients (75%), including grade 3 AEs observed in 5 patients (31%). There were no AEs of grade 4 or 5. After a median of 25 nivolumab doses, 62% of responding patients proceeded to allogeneic stem cell transplantation. ConclusionNivolumab monotherapy demonstrated a high efficacy and safety in R/R cHL patients after BV failure. More patients and longer follow-up may further establish the potential benefit

Ten years of Polish Myeloma Study Group – history and key achievements

Polish Myeloma Study Group (PMSG) was created in 2005 during XXI Congress of Polish Society of Haematology and Transfusion Medicine with the initiative of prof. Anna Dmoszynska as a forum for exchanging experiences and for clinical and scientific cooperation focused on the issue of multiple myeloma (MM). The main aims of PMSG include development of joint study projects, elaboration of unified diagnostic procedures and common treatment algorithms using new drugs. PMSG has established cooperation with international MM study group in Europe. During ten years of activity, the members of PMSG published many papers in peer-review Polish and international journals. In current article some important studies of PMSG are described

Plerixafor for patients who fail cytokine-or chemotherapy-based stem cell mobilization: Results of a prospective study by the Polish Lymphoma Research Group (PLRG)

Autologous hematopoietic stem cell transplantation (autoHSCT) requires collection of sufficient number of hematopoietic stem cells. The goal of this study was to evaluate efficacy of plerixafor used in patients with lymphoid malignancies failing conventional stem cell mobilization.This was a prospective, non-interventional study. All consecutive patients (n = 109) treated with plerixafor in 11 centers were reported. The drug was used either in case of previous mobilization failure (n = 67) or interventionally, in case of insufficient CD34 cell output during current mobilization (n = 42). Successful mobilization was defined as resulting in collection of ≥ 2 × 10 CD34 cells/kg for single autoHSCT or ≥ 4 × 10 CD34 cells/kg for double procedure.The overall rate of successful mobilization was 55% (55% for single and 56% for double autoHSCT). The median total number of collected CD34 cells/kg was 2.4 (range, 0-11.5) for patients intended for a single transplantation while 4.0 (0.6-16.9) for double procedure. The number of circulating CD34 cells increased after the use of plerixafor regardless of baseline values. The median fold increase was 3.3 (0.3-155). Data from this observational study confirm high efficacy of plerixafor used in routine clinical practice as salvage for patients with lymphoid malignancies failing conventional stem cell mobilization

Real-life experiences of letermovir prophylaxis for cytomegalovirus infection in patients after hematopoietic stem cell transplantation: Polish Acute Leukemia Group (PALG) analysis

Introduction: Letermovir (LMV) is a new, cytomegalovirus (CMV)-specific, antiviral drug, approved in 2018 for CMV prophylaxis in patients after allogeneic hematopoietic transplantation. The introduction of letermovir prophylaxis has changed the management of CMV infection: it has reduced the incidence of CMV infections and CMV-related complications, and also improved the overall survival in CMV seropositive patients. However, until recently, due to its high treatment cost, prophylaxis with letermovir has not beeen a standard of care in Poland. Material and methods: To confirm the effectiveness and safety of letermovir prophylaxis, we collected real-life data from eight Polish transplant centers, in which a total of 53 patients were treated with letermovir, including off-label use. Results: LMV is characterized by low toxicity and good tolerability. There were no reports of special adverse events caused by LMV. Conclusions: Our experiences confirm the effectiveness and safety of letermovir prophylaxis, and suggest that this prophylaxis should be started as soon as possible after the infusion of stem cells, preferably no later than day 14. Moreover, our findings indicate that some patients could benefit from extended letermovir prophylaxis beyond 100 days after transplant

High efficacy and safety of VTD as an induction protocol in patients with newly diagnosed multiple myeloma eligible for high dose therapy and autologous stem cell transplantation : a report of the Polish Myeloma Study Group

The present retrospective analysis evaluated the efficacy and safety of the VTD (bortezomib, thalidomide, dexamethasone) regimen in 205 newly‑diagnosed patients with multiple myeloma (MM) eligible for high dose therapy and autologous stem cell transplantation (HDT/ASCT) in routine clinical practice. With a median of 6 cycles (range, 1‑8), at least partial response was achieved in 94.6% and at least very good partial response (VGPR) was achieved in 67.8% of patients. Peripheral neuropathy (PN) grade 2‑4 was observed in 28.7% of patients. In 72% of patients undergoing stem cell mobilization one apheresis allowed the number of stem cells sufficient for transplantation to be obtained. Following HDT/ASCT the sCR rate increased from 4.9 to 14.4% and CR from 27.8 to 35.6%. The results demonstrated that VTD as an induction regimen was highly efficient in transplant eligible patients with MM with increased at least VGPR rate following prolonged treatment (≥6 cycles). Therapy exhibited no negative impact on stem cell collection, neutrophils and platelets engraftment following ASCT. Therapy was generally well tolerated and PN was the most common reason of dose reduction or treatment discontinuation

Age-dependent determinants of infectious complications profile in children and adults after hematopoietic cell transplantation : lesson from the nationwide study

Incidence and outcome of microbiologically documented bacterial/viral infections and invasive fungal disease (IFD) in children and adults after hematopoietic cell transplantation (HCT) were compared in 650 children and 3200 adults in multicenter cross-sectional nationwide study. Infections were diagnosed in 60.8% children and 35.0% adults, including respectively 69.1% and 63.5% allo-HCT, and 33.1% and 20.8% auto-HCT patients. The incidence of bacterial infections was higher in children (36.0% vs 27.6%; p  21 days were risk factors for death from infection. In conclusion, pediatric patients have 2.9-fold higher incidence and 2.5-fold better outcome of infections than adults after HCT